Stock data
Tango Therapeutics, Inc. (TNGX)
Tango Therapeutics, Inc. (TNGX) reported revenue of US$62.38M and net income of -US$101.59M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$62.38M | — | -US$111.29M | -US$101.59M | — |
| 2024 | US$42.07M | — | -US$145.59M | -US$130.30M | — |
| 2023 | US$36.53M | — | -US$114.17M | -US$101.74M | — |
| 2022 | US$24.86M | — | -US$111.07M | -US$108.18M | — |
| 2021 | US$37.04M | — | -US$58.19M | -US$58.23M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$0.00M | -US$55.34M | — |
| 2026-03-31 | US$0.00M | -US$45.51M | — |
| 2025-12-31 | US$0.00M | -US$38.75M | — |
| 2025-09-30 | US$53.81M | US$15.88M | — |
| 2025-06-30 | US$3.18M | -US$38.85M | — |
| 2025-03-31 | US$5.39M | -US$39.88M | — |
| 2024-12-31 | US$4.12M | -US$37.67M | — |
| 2024-09-30 | US$11.61M | -US$29.17M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.